New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials

被引:1
作者
Ogi, Chizuru [1 ,2 ]
Aruga, Atsushi [1 ,2 ]
机构
[1] Tokyo Womens Med Univ, Joint Grad Sch, Shinjuku Ku, Tokyo 1628666, Japan
[2] Waseda Univ, TWIns, Shinjuku Ku, Tokyo 1628666, Japan
关键词
biomarker; cancer; immune monitoring; immunotherapy; regulatory science; vaccine; IMMUNE-RESPONSE; SIPULEUCEL-T; PHASE-II; IMMUNOTHERAPY; LYMPHOCYTES; MELANOMA; TUMOR; VACCINATION; SURVIVAL; CORRELATE;
D O I
10.2217/IMT.14.74
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Aim: This study aimed to derive meaningful parameters for immune monitoring during cancer vaccine development by analysis of the literature. Methods: This retrospective study was based on analysis of clinical trials registered at ClinicalTrials.gov and published data available on PubMed. Results: The most common sample evaluated in immune monitoring was peripheral blood. All trials employed ELISA for detecting a humoral immune response; however, cellular immune assays were not used across trials. Most cellular immune assays failed to correlate with clinical outcome, although results of other methods did. Conclusion: Standardization of the cellular immune assays across trials is important for predicting the effects of therapeutic cancer vaccines when considering the reliability and characteristics of the methods. Currently, assays mostly target detection of T-cell function, such as proliferation and cytokine release; however, T-cell phenotype analysis in peripheral blood and/or tumor sites may also be considered in the future.
引用
收藏
页码:1025 / 1036
页数:12
相关论文
共 34 条
[31]   Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival [J].
Walter, Steffen ;
Weinschenk, Toni ;
Stenzl, Arnulf ;
Zdrojowy, Romuald ;
Pluzanska, Anna ;
Szczylik, Cezary ;
Staehler, Michael ;
Brugger, Wolfram ;
Dietrich, Pierre-Yves ;
Mendrzyk, Regina ;
Hilf, Norbert ;
Schoor, Oliver ;
Fritsche, Jens ;
Mahr, Andrea ;
Maurer, Dominik ;
Vass, Verona ;
Trautwein, Claudia ;
Lewandrowski, Peter ;
Flohr, Christian ;
Pohla, Heike ;
Stanczak, Janusz J. ;
Bronte, Vincenzo ;
Mandruzzato, Susanna ;
Biedermann, Tilo ;
Pawelec, Graham ;
Derhovanessian, Evelyna ;
Yamagishi, Hisakazu ;
Miki, Tsuneharu ;
Hongo, Fumiya ;
Takaha, Natsuki ;
Hirakawa, Kosei ;
Tanaka, Hiroaki ;
Stevanovic, Stefan ;
Frisch, Juergen ;
Mayer-Mokler, Andrea ;
Kirner, Alexandra ;
Rammensee, Hans-Georg ;
Reinhardt, Carsten ;
Singh-Jasuja, Harpreet .
NATURE MEDICINE, 2012, 18 (08) :1254-+
[32]   Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype [J].
Weng, WK ;
Czerwinski, D ;
Timmerman, J ;
Hsu, FJ ;
Levy, R .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4717-4724
[33]   Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer [J].
West, N. R. ;
Kost, S. E. ;
Martin, S. D. ;
Milne, K. ;
deleeuw, R. J. ;
Nelson, B. H. ;
Watson, P. H. .
BRITISH JOURNAL OF CANCER, 2013, 108 (01) :155-162
[34]   Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria [J].
Wolchok, Jedd D. ;
Hoos, Axel ;
O'Day, Steven ;
Weber, Jeffrey S. ;
Hamid, Omid ;
Lebbe, Celeste ;
Maio, Michele ;
Binder, Michael ;
Bohnsack, Oliver ;
Nichol, Geoffrey ;
Humphrey, Rachel ;
Hodi, F. Stephen .
CLINICAL CANCER RESEARCH, 2009, 15 (23) :7412-7420